BriaCell Therapeutics provides an update to the previously announced investigation of alleged illegal trading activity of its publicly traded securities. Upon external forensic analysis of data from various industry sources consistently demonstrating significant settlement share imbalances, and after discussions with 12 individual prime brokers for clarification of these imbalances, the Company has filed formal complaints with the Financial Industry Regulatory Authority and the Canadian Investment Regulatory Organization/ The Company will continue to work with regulatory authorities to combat illegal manipulative trading activities and will provide further updates on this investigation as they become available.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCTX:
- BriaCell announces clinical data from its Phase 2 trial with Bria-IMT regimen
- BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
- BriaCell announces the initiation of GMP manufacturing of Bria-Pros+
- Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
- BriaCell’s Shareholders Approve Directors and Auditors
